Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Galectin Therapeutics Inc (GALT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Galectin's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.380 +0.320    +10.46%
23/04 - Closed. Currency in USD ( Disclaimer )
After Hours
3.350
-0.030
-0.888%
19:35:52 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 235,497
  • Bid/Ask: 3.340 / 3.800
  • Day's Range: 2.990 - 3.550
Galectin 3.380 +0.320 +10.46%

Galectin Therapeutics Inc Company Profile

 
Get an in-depth profile of Galectin Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

9

Equity Type

ORD

Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.

Contact Information

Address 4960 Peachtree Industrial Boulevard Suite 240
Norcross, 30071
United States
Phone 678 620 3186
Fax -

Top Executives

Name Age Since Title
Gilbert S. Omenn 79 2009 Independent Director
Richard E. Uihlein 76 2017 Independent Chairman
Kevin D. Freeman 59 2011 Independent Vice Chairman of the Board
Joel Lewis 51 2017 President, CEO & Director
Gilbert F. Amelio 78 2009 Independent Director
Richard A. Zordani 48 2020 Independent Director
Anatole A. Klyosov 76 2000 Co-founder & Member of the Scientific Board
Marc Rubin 68 2011 Independent Director
Arun J. Sanyal - - Member of Clinical Advisory Board
Brent Tetri - - Member of Clinical Advisory Board
Thomas D. Schiano - - Member of Clinical Advisory Board
Ram Subramanian - - Member of Clinical Advisory Board
Stephen A. Harrison - - Member of Clinical Advisory Board
Mohammad Siddiqui - - Member of Clinical Advisory Board
Elissa J. Schwartz 52 2020 Independent Director
Kary Eldred 49 2018 Independent Director
Kevin H. Mayo - - Member of the Scientific Board
Eric Lawitz - - Member of Clinical Advisory Board
Naga Chalasani - - Member of Clinical Advisory Board
Benjamin S. Carson 72 2023 Independent Director
Harold H. Shlevin 74 2012 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GALT Comments

Write your thoughts about Galectin Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Foli Adebayo
Foli Adebayo Jul 09, 2021 10:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wondering if this is a long play...i got in @3.79
Bartek Kulec
Bartek Kulec Jul 09, 2021 10:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm in 7 years. still waiting for this miracle drug
Bartek Kulec
Bartek Kulec Jul 09, 2021 10:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm in 7 years. still waiting for this miracle drug
Foli Adebayo
Foli Adebayo Jul 09, 2021 10:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any thoughts??
Zapotek Millhouse
Zapotek Millhouse Jun 18, 2021 3:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
was waiting long time to buy.. now paid too much
Kade Smith
Kade Smith May 05, 2021 6:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Earning reports is like the beginning of a Dubstep song. Waiting for the beat to drop.
Kade Smith
Kade Smith Apr 29, 2021 10:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Update on my short, still ITM
Kade Smith
Kade Smith Apr 27, 2021 5:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just took a short position, lets see how ignorant I was!
Stian Nørsterud
Stian Nørsterud Apr 27, 2021 5:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RIP
Yurii Hidden
Azazavr Apr 22, 2021 12:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just closed my position. It was a good deal
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email